赛隆药业集团股份有限公司 详式权益变动报告书 上市公司名称：赛隆药业集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：*ST赛隆 信息披露义务人：海南雅亿共赢科技合伙企业（有限合伙） 住所/通讯地址：海南省海口市龙华区金宇街道南海大道豪苑路1号海 口中关村信息谷创新中心雨林空间孵化器2025-ZC-1758号 股份变动性质：股份增加（协议受让） 签署日期：二〇二五年五月 赛隆药业集团股份有限公司 详式权益变动报告书 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系信息披露义务人根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容 与格式准则第15号——权益变动报告书》《公开发行证券的公司信息披露内容与 格式准则第16号——上市公司收购报告书》及相关的法律、法规及部门规章的有 关规定编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在赛隆药业集团股份有限公司拥有权益的股 份变动情况。 截至本报告书签署日，除本报告书披露的持股信息外，信息披 ...

上海荣正企业咨询服务（集团）股份有限公司 关于 赛隆药业集团股份有限公司 详式权益变动报告书 之 财务顾问核查意见 上海荣正企业咨询服务（集团）股份有限公司 二〇二五年五月 1 声 明 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号—— 权益变动报告书》、《公开发行证券的公司信息披露内容与格式准则第 16 号— —上市公司收购报告书》及其他相关法律、法规及部门规章的规定，上海荣正企 业咨询服务（集团）股份有限公司（以下简称"本财务顾问"）按照行业公认的 业务标准、道德规范，本着诚实守信、勤勉尽责的精神，就本次信息披露义务人 披露的《赛隆药业集团股份有限公司详式权益变动报告书》进行核查，并出具核 查意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 一、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及时， 不存在任何重大遗漏、虚假记载或误导性陈述，并对其真实性、准确性、完整性 和合法性负责。 二、本财务顾问已按照规定 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）控股股东、 实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与海南雅亿共赢科技合伙 企业（有限合伙）（以下简称"海南雅亿"）签署了《关于赛隆药业集团股份有 限公司之股份转让协议》（以下简称《股份转让协议》），蔡南桂先生、唐霖女 士拟向海南雅亿转让其持有的公司 14.16%股份。同时，蔡南桂先生、唐霖女士承 诺自本次交易交割日起至其不再持有上市公司股份之日止，无条件且不可撤销地 承诺放弃行使其所持标的公司剩余股份所对应的除收益权和股票处置权之外的 全部股东权利，上述事项可能导致本公司控股股东及实际控制人发生变更。该事 项尚需取得深圳证券交易所合规性确认后方可实施，能否最终完成及完成时间尚 存在重大不确定性。敬请广大投资者关注相关公告并注意投资风险。 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-028 赛隆药业集团股份有限公司 关于受让方海南雅亿共赢科技合伙企业（有限合 伙）完成工商变更登记暨公司控制权拟发 ...

Group 1 - The Helicobacter pylori concept sector increased by 1.28%, ranking fifth among concept sectors, with 48 stocks rising, including New World and Haisan Pharmaceutical reaching a 20% limit up [1] - Major gainers in the Helicobacter pylori sector included Zhongsheng Pharmaceutical, *ST Sailong, and others, with increases of 8.80%, 7.82%, and 3.77% respectively [1] - The sector saw a net inflow of 599 million yuan from main funds, with 34 stocks receiving net inflows, and five stocks exceeding 50 million yuan in net inflow [2] Group 2 - The top three stocks by net inflow in the Helicobacter pylori sector were Haisan Pharmaceutical (179 million yuan), Zhongsheng Pharmaceutical (177 million yuan), and Jiaoda Onlly (128 million yuan) [2] - The net inflow ratios for Zhongsheng Pharmaceutical, Jiaoda Onlly, and Haisan Pharmaceutical were 42.93%, 18.92%, and 15.92% respectively [3] - The overall performance of the Helicobacter pylori sector was supported by significant trading volumes, with Haisan Pharmaceutical achieving a turnover rate of 39.86% [3]

Market Overview - The Shanghai Composite Index is at 3389.00 points, above the six-month moving average, with a slight increase of 0.04% [1] - The total trading volume of A-shares today is 512.26 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 75 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Meirui New Materials (300848) with a deviation rate of 8.28% and a price increase of 8.72% [1] - Wankong Intelligent Manufacturing (603070) with a deviation rate of 7.52% and a price increase of 9.97% [1] - Hitec High-tech (002023) with a deviation rate of 5.81% and a price increase of 10.01% [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Sichuan Jiuzhou (000801) with a price increase of 3.47% and a deviation rate of 2.56% [2] - Phoenix Light (600071) with a price increase of 3.05% and a deviation rate of 2.47% [2] - Raytheon Micro Power (301050) with a price increase of 4.04% and a deviation rate of 2.26% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002898 证券简称：*ST赛隆（维权） 公告编号：2025-027 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于2025年4月25日披露了《2024年年度报 告》，经审计的年度报告数据显示，公司2024年度利润总额、净利润、扣除非经常性损益后的净利润三 者均为负值，且扣除后的营业收入低于3亿元。根据《深圳证券交易所股票上市规则》第9.3.1条规定， 公司股票交易于2025年4月28日被深圳证券交易所实施退市风险警示。若公司2025年度出现《深圳证券 交易所股票上市规则》第9.3.12条所规定的关于终止公司股票上市交易的相关情形之一，公司股票将面 临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于2025年5月18日与海南雅亿共赢科技合伙企业 （有限合伙）（以下简称"海南雅亿"） 签署了《关于赛隆药业集团股份有限公司之股份转让协议》 （以下简称《 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-027 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报告数据显示，公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利润三者均为负值，且扣除后 的营业收入低于 3 亿元。根据《深圳证券交易所股票上市规则》第 9.3.1 条规 定，公司股票交易于 2025 年 4 月 28 日被深圳证券交易所实施退市风险警示。若 公司 2025 年度出现《深圳证券交易所股票上市规则》第 9.3.12 条所规定的关于 终止公司股票上市交易的相关情形之一，公司股票将面临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与 海南雅亿共赢科技合伙企业（有限合伙）（以下简称"海南雅亿"） 签署了《关 于赛隆药业集团股份有限公司之股份转让协议》（以下简称《 ...

Core Viewpoint - The transfer of 14.16% of shares from the controlling shareholders of Sailong Pharmaceutical to Hainan Yayi will result in a change of control, with Hainan Yayi becoming the new controlling shareholder, although the company will have no actual controller [1][3]. Group 1: Share Transfer and Control Change - The controlling shareholders Cai Nanguai and Tang Lin plan to transfer their shares at a price of 8 yuan per share, totaling 199 million yuan [1]. - After the transfer, Hainan Yayi will hold 24.60% of the voting rights in Sailong Pharmaceutical, making it the controlling shareholder [3]. - Hainan Yayi was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [3]. Group 2: Financial Performance and Risks - Sailong Pharmaceutical has been facing financial difficulties, with only one profitable year since 2020, and has reported losses in other years [4]. - Revenue figures from 2020 to 2024 were 121 million yuan, 247 million yuan, 264 million yuan, 311 million yuan, and 264 million yuan, while net profits were -67.22 million yuan, -23.34 million yuan, -37.31 million yuan, 9.534 million yuan, and -33.1456 million yuan respectively [4]. - The first quarter of 2025 showed a revenue of 54.09 million yuan, a year-on-year decrease of 22.2%, and a net loss of 1.04 million yuan, a decline of 163.9% year-on-year [4]. Group 3: Regulatory and Market Context - Sailong Pharmaceutical's stock was placed under delisting risk warning on April 28, 2025, due to negative profit figures and revenue below 300 million yuan [5]. - The company has outlined strategies to improve its financial situation, including expanding sales channels, increasing marketing efforts, and optimizing internal management [6].

Group 1: Company Announcements - Light Media's controlling shareholder plans to reduce its stake by no more than 29.24 million shares, accounting for up to 1% of the total share capital, to lower debt and improve financial structure [1] - Xinjiang Haoyuan intends to change its name to "Wanqing Energy" and its stock abbreviation accordingly [2] - Xunbang Intelligent plans to acquire controlling shares of Wuxi Indichip Microelectronics, focusing on the automotive chip sector [3] - Kangping Technology intends to acquire 100% of Suolu Electronics for 198 million yuan to enhance core competitiveness [4] - Shentong Express reported April revenue of 4.118 billion yuan, a year-on-year increase of 16.39% [5] - Wenzhou Hongfeng's controlling shareholder plans to reduce its stake by no more than 4.37 million shares, accounting for 1% of total share capital [8] - Changyang Technology plans to invest 29.9 million yuan in Ningbo Huizhixing New Materials [9] - Zhejiang Agricultural Holdings intends to publicly transfer 100% of its subsidiary Huadong Pharmaceutical, valued at 369 million yuan [10] - *ST Jinguang faces delisting risk due to stock price falling below 1 yuan for 10 consecutive trading days [11] - Huibo Yuntong plans to acquire 67.91% of Baode Computer to enhance its competitive edge [12] - Xinhua Group intends to change its name to "Yingxin Development" [13] - Purang Co. plans to reduce its stake by no more than 24,800 shares due to personal funding needs [14] - Xinhecheng plans to participate in a land auction for a commercial plot in Hangzhou, with a starting price of 1.037 billion yuan [15] - *ST Sailong's controlling shareholder plans to transfer 14.16% of shares, potentially changing control [16] - Gaoweida's controlling shareholder plans to reduce its stake by no more than 13.27 million shares due to funding needs [17] - Tianli Lithium Energy's shareholder plans to reduce its stake by no more than 3% [18] - Baijia Qiancheng's shareholder plans to reduce its stake by no more than 9.42 million shares [19] - United Optoelectronics is planning to issue shares to acquire Dongguan Changyi Optoelectronics [20] - Meg Intelligent plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [21] Group 2: Industry Insights - The express delivery industry shows growth, with Shentong Express and Yunda reporting revenue increases of 16.39% and 5.84% respectively in April [5][20] - The automotive chip sector is highlighted as a key investment area, with Xunbang Intelligent's acquisition of Indichip Microelectronics [3] - The energy sector is seeing name changes and strategic shifts, as seen with Xinjiang Haoyuan's rebranding to Wanqing Energy [2] - The pharmaceutical sector is undergoing restructuring, with Zhejiang Agricultural Holdings planning to divest its pharmaceutical subsidiary [10] - The technology sector is active in mergers and acquisitions, with Huibo Yuntong's acquisition of Baode Computer [12]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-026 赛隆药业集团股份有限公司 关于控股股东、实际控制人签署《股份转让协议》 暨公司控制权拟发生变更的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别风险提示： 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司""标的公司"） 控股股东、实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与海南雅亿共 赢科技合伙企业（有限合伙）（以下简称"海南雅亿"） 签署了《关于赛隆药 业集团股份有限公司之股份转让协议》（以下简称《股份转让协议》），蔡南桂 先生、唐霖女士拟向海南雅亿转让其持有的公司 14.16%股份（对应的股票数量 为 24,912,205 股，以下简称"标的股份"）。同时，蔡南桂先生、唐霖女士承 诺自本次交易交割日起至其不再持有上市公司股份之日止，无条件且不可撤销地 承诺放弃行使其所持标的公司剩余股份所对应的除收益权和股票处置权之外的 全部股东权利。标的股份作价为人民币 8 元/股 ...